Overview
Concord Medical's H1 2025 revenue falls 8.3% yr/yr to RMB200.6 mln (US$28.0 million)
Net loss narrows to RMB27.1 mln (US$3.8 million) from RMB172.3 mln last year
Hospital business revenue up 11.1% due to proton therapy operations at Guangzhou Concord Cancer Hospital
Outlook
Company to advance proton therapy and enhance precision radiotherapy understanding
Concord Medical aims to expand access to advanced diagnostic technologies
Company plans to strengthen patient confidence in precision radiotherapy
Concord Medical committed to improving patient access to innovative medications
Result Drivers
PROTON THERAPY - Hospital business revenue increased by 11.1% due to the commencement of proton therapy operations at Guangzhou Concord Cancer Hospital
NETWORK BUSINESS DECLINE - Network business revenue fell 41.3% due to decreased demand for medical equipment and software and non-renewal of expired contracts
COST EFFICIENCY - Gross loss margin improved due to adjustments in revenue structure and strategic focus on enhancing operational efficiency and reducing costs
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Revenue | RMB 200.60 mln | ||
H1 EPS | RMB 0.21 | ||
H1 Net Income | -RMB 27.10 mln | ||
H1 Adjusted EBITDA | -RMB 62.20 mln |
Press Release: ID:nPnbGX85Ba
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)